1,089 results on '"Geier Andreas"'
Search Results
2. Incremental prognostic utility of congestion markers in cardiac transthyretin amyloidosis
3. AmyKoS—a German real-world prospective cohort study of patients with suspected and proven amyloidosis
4. Tafamidis for cardiac transthyretin amyloidosis: application in a real-world setting in Germany
5. Evaluation of four chatbots in autoimmune liver disease: A comparative analysis
6. Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients
7. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events
8. Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study
9. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
10. Diagnostik: Fibrosescores
11. Pathophysiologie: Lipidstoffwechsel
12. Ein Ausblick in die Zukunft
13. Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol
14. Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors
15. Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study
16. A global research priority agenda to advance public health responses to fatty liver disease
17. Systemtherapie des hepatozellulären Karzinoms: mehr als eine „palliative“ Therapie?
18. 72/w mit akutem Abdomen: Vorbereitung auf die Facharztprüfung: Fall 24
19. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis
20. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study
21. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling
22. The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C
23. Treating hepatitis D with bulevirtide – Real-world experience from 114 patients
24. THU-269-YI Effects of semaglutide, Peptide YY3-36 and empagliflozin on metabolic dysfunctions-associated fatty steatotic liver disease in diet-induced obese rats with chronic nitric oxide synthaseinhibition
25. WED-249 Improved risk stratification by combination of FIB-4 with FGF21 serum levels in steatotic liver disease
26. THU-164-YI Evaluation of four chatbots in autoimmune liver disease: a comparative analysis
27. FRI-098 Feasibility of bedside ultrasonography of rectus femoris muscle for sarcopenia diagnosis in liver cirrhosis
28. FRI-103-YI Screening and assessing Sarcopenia in liver cirrhosis: feasibility and implications for clinical outcomes
29. OS-112-YI Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapybased systemic therapy
30. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
31. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance
32. Effects of semaglutide, Peptide YY3-36 and empagliflozin on metabolic dysfunction associated fatty steatotic liver disease in diet-induced obese rats with chronic nitric oxide synthase-inhibition
33. Effects of antagonists of the NPY-2 receptor, semaglutide, PYY3-36, and empagliflozin on metabolic dysfunction-associated steatotic liver disease in diet-induced obese rats
34. Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis—A real-world case series
35. Cardio-Hepatic Interaction in Cardiac Amyloidosis
36. Real-World Burden of Nonalcoholic Steatohepatitis
37. Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information
38. Diabetes mellitus und Fettlebererkrankungen
39. Amendment „Neue Nomenklatur zur MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease; metabolische Dysfunktion assoziierte steatotische Lebererkrankung) " zur S2k-Leitlinie „Nicht-alkoholische Fettlebererkrankung" (v.2.0/April 2022) der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)
40. PNPLA3 fatty liver allele was fixed in Neanderthals and segregates neutrally in humans.
41. Assessing physician preferences on future therapeutic options and diagnostic practices in non-alcoholic steatohepatitis
42. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis
43. What is the impact of metabolic dysfunction associated steatotic liver disease on drug transport and metabolism?
44. S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Kurzversion
45. S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0
46. Sequential or up-front triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma (HCC): MONTBLANC.
47. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion
48. LiverPRO for the Prediction of Significant Liver Fibrosis in Primary Care: Development, Validation, and Prognostic Evaluation of a Novel Score
49. The inhibition of YAP Signaling Prevents Chronic Biliary Fibrosis in the Abcb4-/- Model by Modulation of Hepatic Stellate Cell and Bile Duct Epithelium Cell Pathophysiology
50. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.